

Supplementary Table 3. Clinical characteristics of study patients by timing of early statin administration

Variables	Timing of early statin administration				P
	No statins (n=283)	<12 hours (n=191)	12–24 hours (n=187)	24–72 hours (n=196)	
Demographic information					
Age	70.4±12.9	68.4±11.9	67.6±13.0	68.0±12.5	0.06
Male sex	144 (50.9)	123 (64.4)	112 (59.9)	115 (58.7)	0.03
Premorbid mRS score=0	226 (79.9)	168 (88.0)	167 (89.3)	174 (88.8)	0.01
Admission year, 2011–2015	158 (55.8)	160 (83.8)	141 (75.4)	133 (67.9)	<0.01
Stroke information					
NIHSS score at arrival	15 (9–20)	11 (6–17)	11 (6–17)	11.5 (6–18)	<0.01
Onset to treatment delay (hour)	2.8 (1.7–6.0)	3.9 (1.8–11.5)	2.9 (1.6–6.9)	2.5 (1.7–5.9)	0.04
Recanalization treatment					<0.01
Intravenous thrombolysis alone	71 (25.1)	57 (29.8)	71 (38.0)	81 (41.3)	
Endovascular therapy alone	88 (31.1)	87 (45.5)	61 (32.6)	46 (23.5)	
Combined	124 (43.8)	47 (24.6)	55 (29.4)	69 (35.2)	
NIHSS score after treatment	14 (6–20)	8 (4–15)	8 (4–13)	8 (4–15)	<0.01
Stroke mechanism					<0.01
Large artery atherosclerosis	44 (15.5)	78 (40.8)	62 (33.2)	43 (21.9)	
Small vessel occlusion	1 (0.4)	14 (7.3)	8 (4.3)	10 (5.1)	
Cardioembolism	172 (60.8)	59 (30.9)	78 (41.7)	104 (53.1)	
Other determined causes	19 (6.7)	9 (4.7)	5 (2.7)	8 (4.1)	
Undetermined cause	47 (16.6)	31 (16.2)	34 (18.2)	31 (15.8)	
Vascular risk factors					
Hypertension	174 (61.5)	138 (72.3)	132 (70.6)	135 (68.9)	0.05
Diabetes	70 (24.7)	60 (31.4)	48 (25.7)	54 (27.6)	0.42
Hyperlipidemia	45 (15.9)	57 (29.8)	59 (31.6)	65 (33.2)	<0.01
Atrial fibrillation	158 (55.8)	48 (25.1)	66 (35.3)	91 (46.4)	<0.01
Regular smoking	82 (29.0)	91 (47.6)	76 (40.6)	78 (39.8)	<0.01
Pre-stroke antithrombotics	153 (54.1)	62 (32.5)	71 (38.0)	92 (46.9)	<0.01
Pre-stroke statins	51 (18.0)	42 (22.0)	47 (25.1)	60 (30.6)	0.01
Laboratory information					
White cell count (μL)	8,276±3,474	8,572±2,868	8,375±3,274	8,324±3,075	0.79
Hemoglobin (g/dL)	13.4±2.0	13.9±2.0	13.6±2.0	13.6±2.0	0.05
Initial glucose (mg/dL)	137±49	141±58	133±49	136±46	0.48
HbA1c (%)	6.0±0.9	6.2±1.2	6.2±1.1	6.3±1.1	0.07
Total cholesterol (mg/dL)	160±34	172±49	167±42	176±41	<0.01
HDL cholesterol (mg/dL)	46±13	43±11	44±11	46±11	0.04
Triglycerides (mg/dL)	99±57	116±68	111±72	109±60	0.03
LDL cholesterol (mg/dL)	95±29	106±41	101±36	108±38	<0.01
Systolic blood pressure (mmHg)	150±27	155±28	153±29	151±26	0.21
Diastolic blood pressure (mmHg)	81±16	84±18	83±20	81±18	0.22
Outcome information					
mRS score at 3 months					<0.01
0	45 (15.9)	47 (24.6)	42 (22.5)	43 (21.9)	
1	25 (8.8)	36 (18.8)	33 (17.6)	43 (21.9)	
2	36 (12.7)	27 (14.1)	34 (18.2)	23 (11.7)	
3	32 (11.3)	27 (14.1)	25 (13.4)	32 (16.3)	
4	39 (13.8)	15 (7.9)	18 (9.6)	19 (9.7)	
5	53 (18.7)	24 (12.6)	21 (11.2)	24 (12.2)	
6	53 (18.7)	15 (7.9)	14 (7.5)	12 (6.1)	
Symptomatic HT	30 (10.6)	12 (6.3)	3 (1.6)	7 (3.6)	<0.01

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HT, hemorrhage transformation.